Please provide your email address to receive an email when new articles are posted on . MADRID — Hossein Borghaei, DO, MS, discussed results from the ALINA study on ALK-positive non-small cell lung ...

(RTTNews) - Genentech, Inc., affiliated to Swiss drug major Roche Holding AG (RHHBY), announced Wednesday results from the primary analysis of the Phase III ALINA study of Alecensa (alectinib) in ...

Alecensa achieved a 4-year OS rate of 98.4% in resected ALK-positive early-stage NSCLC, outperforming chemotherapy. The ALINA study showed a 65% reduction in disease recurrence or death risk with ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced results from the primary analysis of the Phase III ALINA study ...

– ALINA data demonstrate Alecensa reduces disease recurrence in the early setting for people with ALK-positive non-small cell lung cancer (NSCLC), building on its long-established benefit in the ...

Results showed treatment with alectinib reduced the risk of disease recurrence or death by 76%. The Food and Drug Administration (FDA) has approved Alecensa (alectinib) for adjuvant treatment in ...

Roche Holding AG RHHBY announced that the late-stage study evaluating Alecensa (alectinib) met its primary endpoint of disease-free survival (DFS) in the treatment of early-stage lung cancer. The ...

Roche Holdings AG (OTC:RHHBY) announced that the Phase 3 ALINA study evaluating Alecensa (alectinib), compared with platinum-based chemotherapy, met its primary endpoint of disease-free survival (DFS) ...